Endothelium dysfunction, which is often defined as a decrease in NO bioavailability, is one
of the earliest manifestations of endothelium-impaired function disorders, including …

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are considered
first-line therapeutic agents for the prevention of coronary heart disease and atherosclerotic …

Knowledge about the function of endothelial nitric oxide synthase (eNOS), and its regulation
in pathophysiological states has tremendously increased. It is now clear that diminished …

Endothelial dysfunction and atherosclerosis are associated with an inflammation-induced
decrease in endothelial nitric oxide synthase (eNOS) expression. Based on the differences …

Objective: We investigated the effects of the statins, cerivastatin and fluvastatin, on the
induction of nitric oxide (NO) production in vascular smooth muscle cells (VSMC) stimulated …

Background and Purpose—Thrombosis superimposed on atherosclerosis causes
approximately two thirds of all brain infarctions. We previously demonstrated that statins …

Objective—Three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) are known to enhance vascular expression of endothelial (eNOS) and inducible …

Significance: Cardiovascular diseases (CVD) represent a major public health burden. High
low-density lipoprotein (LDL)-cholesterol is a recognized pathogenic factor for …

Statins are inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a ubiquitous
enzyme critical for the biosynthesis of cholesterol. Because of their cholesterol-lowering …

Statins inhibit cholesterol synthesis and produce pleiotropic, cholesterol-independent effects
including endothelial NO synthase (eNOS) stimulation and increased expression. However …